We appreciate the interesting comments made by Drs Contractor and Cooper.
To the Editor-Treatment of asystole caused by vagal nerve stimulator
We read with great interest the case report by Ratajczak and colleagues 1 of late-onset asystolic episodes in a patient with a vagal nerve stimulator that were successfully treated by pacemaker implantation.
In this particular case, excessive iatrogenic parasympathetic stimulation of the cardiac conduction system with the vagal stimulator was presumed to be the mechanism of bradyarrhythmias. A variety of different clinical conditions could result in similar cardioinhibition as a result of endogenously enhanced parasympathetic tone, such as cardioinhibitory syncope, carotid sinus syndrome, and ictal asystole. Pacemaker implantation is a viable treatment option in such cases. However, complications rates due to a pacemaker during long-term follow-up are not low, ranging from 7.5% to almost 10% of patients. In addition, chronic pacing of the right ventricle could be detrimental to cardiac function. 2 Cardioneuroablation is an emerging option for treatment of cardioinhibitory neurocardiogenic syncope, with promising long-term results. 3 This minimally invasive technique is based on radiofrequency ablation of the main epicardial parasympathetic ganglia in the heart, with the aim of modifying the abnormally enhanced cardiac vagal tone. Using this ablation procedure in our center, we successfully treated a patient with ictal asystole and were able to convert the patient's dramatic seizures with severe cerebral hypoperfusion to short focal seizures with minimal motor sign. Therefore, we strongly believe that cardioneuroablation also could be considered in the presented case.
Bor Antolic, MD, PhD bor.antolic@kclj.si David Zizek, MD, PhD
Department of Cardiology University Medical Center Ljubljana
Ljubljana, Slovenia
Reply to the Editor-Treatment of asystole caused by vagal nerve stimulator
We thank Drs Antolic and Zizek for their thoughtful review of our case report on the use of a permanent pacemaker in a patient with late-onset asystolic episodes related to use of a nerve stimulator. 1 Cardioneuroablation is a new technology in which the autonomic ganglion in the left atrium is targeted for denervation as a treatment for neurally mediated syncope, asystolic, and postictal syncope. The data are limited, based on small observational studies and case reports [2] [3] [4] [5] ; no randomized controlled trial has been completed yet.
Alteration in autonomic function can lead to deleterious effects on the heart, such as arrhythmias and sudden cardiac death, which are unknown in this patient population.
Theresa Ratajczak, MD*
To the Editor-The proper usage of electroanatomic mapping-guided cardioneuroablation
We read with great interest the case report of cardioneuroablation in ictal asystole by Antolic and colleagues.
1 They tried to ablate ganglionated plexi (GPs) by targeting fractionated electrograms (EGMs) in the anatomic areas where GPs for sinus and atrioventricular node innervation are located. The usage of fractionated EGMs for cardioneuroablation was first defined by our group. 2, 3 In our protocol, bipolar endocardial atrial EGMs were evaluated for amplitude and number of deflections at special filter settings and sweep speed. All EGMs were divided into the following subgroups: normal, low-amplitude fractionated EGM (LAFE), and high-amplitude fractionated EGM (HAFE). Then, the sites demonstrating HAFE or LAFE pattern in a region that is consistent with probable localization of GPs were tagged as ablation targets in both atria. Other sites demonstrating LAFE pattern were accepted as scar tissue and excluded from the assessment.
In the present work, the authors should have defined why all sites demonstrating fractionated pattern were not targeted, because it is well known that superior and inferior left atrial GPs are located between the left pulmonary veins (PVs) and the left atrial appendage and within the fat pad below the left inferior PV, respectively. 4 In our research, we demonstrated that both superior and inferior left atrial GPs might be detected by using fractionated EGMs. 3 Although the majority of the fractionated EGMs were detected at the insertion of the right PVs and at the superior vena cava insertions or surrounding the coronary sinus ostium in the left and right atria, respectively, the number of fractional EGMs was higher than that found in the interatrial septum. 3 The main problem for the cardioneuroablation procedure is to localize GPs. Our new electroanatomic mapping-guided strategy may be used to define GP sites by using conventional electrophysiological equipment to achieve complete vagal denervation. In their comments they describe the approach of targeting low-and high-amplitude fractionated electrograms (LAFE and HAFE) in anatomical regions that are consistent with probable localization of ganglionated plexi. 2 Although some authors have tried to define procedural targets and endpoints of cardioneuroablation, 3 they are not generally agreed upon; consequently, multiple different methods of achieving the same clinical endpoint are currently present.
In our case, the aim was to achieve sufficient vagal denervation to prevent heightened parasympathetic tone during focal epileptic seizure, which induced sinus arrest and syncope. To achieve this goal, we decided to target fractionated potentials in the anatomically defined areas. Furthermore, we decided to limit our ablation lesions
